Reply

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 3, 2008, Pages 786-

  Limb, Susan L ^a   Lee, Charles E ^a   Starke, Peter R ^a   Chowdhury, Badrul A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ANAPHYLAXIS; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 40049097942     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.12.1187     Document Type: Letter

References (3)

1. Barry P.J., O'Mahony A., Finnegan C., and O'Connor T.M. Delayed allergic reactions to omalizumab: are patients reporting all cases?. J Allergy Clin Immunol 121 (2008) 785-786
2. Rogers A.S., Israel E., Smith C.R., Levine D., McBean A.M., Valente C., et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 148 (1988) 1596-1600
3. Scott H.D., Rosenbaum S.E., Waters W.J., Colt A.M., Andrews L.G., Juergens J.P., et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 70 (1987) 311-316